Should I buy or sell Anavex Life Sciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVXL shares. View AVXL analyst ratings or view top-rated stocks .

What is Anavex Life Sciences' stock price target for 2024?

1 brokerages have issued 1 year price objectives for Anavex Life Sciences' shares. Their AVXL share price targets range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price. View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts .

How have AVXL shares performed in 2024?

Anavex Life Sciences' stock was trading at $9.31 on January 1st, 2024. Since then, AVXL shares have decreased by 59.2% and is now trading at $3.80. View the best growth stocks for 2024 here .

Are investors shorting Anavex Life Sciences?

Anavex Life Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 22,120,000 shares, an increase of 10.6% from the March 15th total of 20,000,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the days-to-cover ratio is currently 17.3 days. View Anavex Life Sciences' Short Interest .

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AVXL earnings forecast .

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) released its earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04.

What ETF holds Anavex Life Sciences' stock?

iShares Neuroscience and Healthcare ETF holds 9,668 shares of AVXL stock, representing 1.85% of its portfolio.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO) , POET Technologies (POETF) , Brainstorm Cell Therapeutics (BCLI) , LadRx (CYTR) , SharkNinja (SN) , Novavax (NVAX) , Geron (GERN) , VASCO Data Security International (VDSI) , Sorrento Therapeutics (SRNE) and OPKO Health (OPK) .

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.11%) and Fiduciary Alliance LLC (0.02%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus , Elliot Favus , Peter DO Donhauser and Sandra Boenisch . View institutional ownership trends .

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVXL

Anavex Life Sciences (AVXL) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AVXL Stock Alerts

$3.80

-0.27 (-6.63%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.79
▼
$4.08
50-Day Range: $4.07
▼
$6.14
52-Week Range: $3.79
▼
$10.45

Volume: 1.66 million shs
Average Volume: 1.43 million shs
Market Capitalization: $312.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.00

Get Anavex Life Sciences alerts:

Anavex Life Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 952.6% Upside
$40.00 Price Target
Short Interest: Bearish
26.94% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: 0.12
Based on 10 Articles This Week
Insider Trading: Selling Shares
$374,972 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.57) to ($0.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.33 out of 5 stars

Medical Sector

288th out of 918 stocks

Biological Products, Except Diagnostic Industry

41st out of 149 stocks

3.5

Analyst's Opinion

Consensus Rating
Anavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Anavex Life Sciences has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
26.94% of the outstanding shares of Anavex Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Anavex Life Sciences has a short interest ratio ("days to cover") of 17.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Anavex Life Sciences has recently increased by 10.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Anavex Life Sciences does not currently pay a dividend.
Dividend Growth
Anavex Life Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Anavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Anavex Life Sciences is -0.83.

2.8

News and Social Media Coverage

News Sentiment
Anavex Life Sciences has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Anavex Life Sciences this week, compared to 3 articles on an average week.
Search Interest
28 people have searched for AVXL on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
MarketBeat Follows
9 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anavex Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $374,972.00 in company stock.
Percentage Held by Insiders
11.60% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.55% of the stock of Anavex Life Sciences is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.57) to ($0.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anavex Life Sciences is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anavex Life Sciences is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anavex Life Sciences has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Anavex Life Sciences Stock (NASDAQ:AVXL)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

AVXL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVXL Stock News Headlines

April 2, 2024 | insidertrades.com

Insider Selling: Anavex Life Sciences Corp. (NASDAQ:AVXL) CEO Sells 73,380 Shares of Stock

April 17, 2024 | americanbankingnews.com

Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Increases By 10.6%

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | morningstar.com

Anavex Life Sciences Corp

April 16, 2024 | prnewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL

April 15, 2024 | prnewswire.com

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit

April 15, 2024 | prnewswire.com

Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL

April 13, 2024 | prnewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | stockhouse.com

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the Firm

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXL

April 12, 2024 | prnewswire.com

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm

April 11, 2024 | stockhouse.com

IMPORTANT DEADLINE ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

April 11, 2024 | globenewswire.com

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

April 10, 2024 | stockhouse.com

Investors who lost money on Anavex Life Sciences Corporation (AVXL) should contact Levi & Korsinsky about pending Class Action - AVXL

April 10, 2024 | prnewswire.com

Contact Levi & Korsinsky by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL)

April 9, 2024 | prnewswire.com

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm

April 8, 2024 | prnewswire.com

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit

April 8, 2024 | prnewswire.com

Anavex Life Sciences Corporation Class Action: Levi & Korsinsky Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL

April 5, 2024 | stockhouse.com

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

April 5, 2024 | prnewswire.com

Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL

April 4, 2024 | markets.businessinsider.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXL

April 4, 2024 | prnewswire.com

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit

April 3, 2024 | prnewswire.com

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for Investors - Contact Levi & Korsinsky

April 2, 2024 | msn.com

Senate faces tough choice on Speaker Johnson’s Ukraine vision

April 2, 2024 | prnewswire.com

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL

See More Headlines

Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AVXL
CUSIP: N/A
CIK: 1314052
Web: www.anavex.com
Phone: (844) 689-3939
Fax: N/A
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $40.00
High Stock Price Target: $40.00
Low Stock Price Target: $40.00
Potential Upside/Downside: +895.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.32%
Return on Assets: -27.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.85
Quick Ratio: 11.85

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.73 per share
Price / Book: 2.32

Miscellaneous

Outstanding Shares: 82,110,000
Free Float: 72,588,000
Market Cap: $330.08 million
Optionable: Optionable
Beta: 0.56

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Christopher U. Missling M.B.A. (Age 58)
M.S., Ph.D., President, CEO, Secretary & Director
Comp: $828.25k
Ms. Sandra Boenisch CPA (Age 43)
CGA, Principal Financial Officer & Treasurer
Comp: $194.36k
Mr. Stephan Toutain M.B.A. (Age 58)
M.S., Senior VP of Operations & COO
Dr. Walter E. Kaufmann M.D.
Chief Scientific Officer
Clint Tomlinson
VP of Corporate
Dr. Adebayo Laniyonu Ph.D.
Senior Vice President of Nonclinical Development
Dr. Edward R Hammond M.D.
M.P.H., Ph.D., Chief Medical Officer
Dr. Kun Jin Ph.D.
Head of Biostatistics
Mr. David Goldberger R.Ph.
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVXL Stock Analysis - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings or view top-rated stocks.
What is Anavex Life Sciences' stock price target for 2024?: 1 brokerages have issued 1 year price objectives for Anavex Life Sciences' shares. Their AVXL share price targets range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price.
View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts.
How have AVXL shares performed in 2024?: Anavex Life Sciences' stock was trading at $9.31 on January 1st, 2024. Since then, AVXL shares have decreased by 59.2% and is now trading at $3.80.
View the best growth stocks for 2024 here.
Are investors shorting Anavex Life Sciences?: Anavex Life Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 22,120,000 shares, an increase of 10.6% from the March 15th total of 20,000,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the days-to-cover ratio is currently 17.3 days.
View Anavex Life Sciences' Short Interest.
When is Anavex Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AVXL earnings forecast.
How were Anavex Life Sciences' earnings last quarter?: Anavex Life Sciences Corp. (NASDAQ:AVXL) released its earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04.

What ETF holds Anavex Life Sciences' stock?: iShares Neuroscience and Healthcare ETF holds 9,668 shares of AVXL stock, representing 1.85% of its portfolio.
What other stocks do shareholders of Anavex Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).
Who are Anavex Life Sciences' major shareholders?: Anavex Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.11%) and Fiduciary Alliance LLC (0.02%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends.
How do I buy shares of Anavex Life Sciences?: Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVXL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Anavex Life Sciences (AVXL) Stock Price, News & Analysis

Anavex Life Sciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Anavex Life Sciences Stock (NASDAQ:AVXL)

AVXL Stock Price History

AVXL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AVXL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™